MA58087B1 - Nouveaux dérivés de méthylquinazolinone - Google Patents

Nouveaux dérivés de méthylquinazolinone

Info

Publication number
MA58087B1
MA58087B1 MA58087A MA58087A MA58087B1 MA 58087 B1 MA58087 B1 MA 58087B1 MA 58087 A MA58087 A MA 58087A MA 58087 A MA58087 A MA 58087A MA 58087 B1 MA58087 B1 MA 58087B1
Authority
MA
Morocco
Prior art keywords
methylquinazolinone
derivatives
new
compound
formula
Prior art date
Application number
MA58087A
Other languages
English (en)
Inventor
Daniel Hunziker
Cosimo Dolente
David Stephen HEWINGS
Daniela Krummenacher
Piergiorgio Francesco Tommaso PETTAZZONI
Juergen Wichmann
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of MA58087B1 publication Critical patent/MA58087B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Combines (AREA)
  • Harvester Elements (AREA)

Abstract

L'invention concerne un nouveau composé ayant la formule générale (I), ou un sel pharmaceutiquement acceptable de celui-ci. Le composé de formule (I) peut être utilisé en tant que médicament.
MA58087A 2019-12-10 2020-12-08 Nouveaux dérivés de méthylquinazolinone MA58087B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214941 2019-12-10
EP20817377.3A EP4073065B1 (fr) 2019-12-10 2020-12-08 Nouveaux dérivés de methylquinazolinone
PCT/EP2020/084976 WO2021116055A1 (fr) 2019-12-10 2020-12-08 Nouveaux dérivés de méthylquinazolinone

Publications (1)

Publication Number Publication Date
MA58087B1 true MA58087B1 (fr) 2025-04-30

Family

ID=68848113

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58087A MA58087B1 (fr) 2019-12-10 2020-12-08 Nouveaux dérivés de méthylquinazolinone

Country Status (29)

Country Link
US (2) US12116349B2 (fr)
EP (2) EP4483882A3 (fr)
JP (2) JP7108146B2 (fr)
KR (1) KR102836833B1 (fr)
CN (2) CN114787156B (fr)
AR (1) AR122351A1 (fr)
AU (1) AU2020403443B2 (fr)
CL (1) CL2022001529A1 (fr)
CO (1) CO2022008968A2 (fr)
CR (1) CR20220251A (fr)
DK (1) DK4073065T3 (fr)
ES (1) ES3023264T3 (fr)
FI (1) FI4073065T3 (fr)
HR (1) HRP20250418T1 (fr)
HU (1) HUE071148T2 (fr)
IL (2) IL316473A (fr)
LT (1) LT4073065T (fr)
MA (1) MA58087B1 (fr)
MX (1) MX2022006783A (fr)
PE (1) PE20221778A1 (fr)
PH (1) PH12022551119A1 (fr)
PL (1) PL4073065T3 (fr)
PT (1) PT4073065T (fr)
RS (1) RS66721B1 (fr)
SI (1) SI4073065T1 (fr)
TW (2) TWI877268B (fr)
UA (1) UA128299C2 (fr)
WO (1) WO2021116055A1 (fr)
ZA (2) ZA202204675B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020403082A1 (en) * 2019-12-10 2022-05-12 F. Hoffmann-La Roche Ag New BRAF inhibitors as paradox breakers
PH12022551119A1 (en) 2019-12-10 2023-08-23 Hoffmann La Roche New methylquinazolinone derivatives
TW202426436A (zh) 2020-06-09 2024-07-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和病症之化合物
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
IL307964A (en) * 2021-06-09 2023-12-01 Chugai Pharmaceutical Co Ltd Combined treatment for cancer
CA3216220A1 (fr) * 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Association d'un inhibiteur de braf particulier ("paradox breaker") et d'un antagoniste de liaison a l'axe pd-1 pour une utilisation dans le traitement du cancer
MX2023014629A (es) * 2021-06-09 2024-01-30 Hoffmann La Roche Nuevas formas solidas de (3r)-n-[2-ciano-4-fluoro-3-(3-metil-4-oxo -quinazolin-6-il)oxi-fenil]-3-fluoro-pirrolidin-1-sulfonamida.
KR20240041917A (ko) 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4426305A1 (fr) 2021-11-04 2024-09-11 F. Hoffmann-La Roche AG Nouvelle utilisation d'un composé quinazolinone pour le traitement du cancer
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
EP4618994A1 (fr) 2022-11-18 2025-09-24 F. Hoffmann-La Roche AG Composé de quinazolinone en tant qu'inhibiteur de braf pour le traitement d'un cancer solide avancé ou de métastases
WO2024126660A1 (fr) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Polythérapie pour le traitement du cancer
TW202438072A (zh) * 2022-12-15 2024-10-01 瑞士商赫孚孟拉羅股份公司 製備喹唑啉酮衍生物之方法
KR20260032991A (ko) 2023-07-04 2026-03-10 에프. 호프만-라 로슈 아게 (3r)-n-[2-시아노-4-플루오로-3-(3-메틸-4-옥소-퀴나졸린-6-일)옥시-페닐]-3-플루오로-피롤리딘-1-설폰아미드의신규 고체 형태
WO2025108405A1 (fr) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 Préparation d'un dérivé de quinazolinone destiné à être utilisé en tant qu'inhibiteur de kinase, et son utilisation
TW202545530A (zh) * 2024-01-17 2025-12-01 大陸商海思科醫藥集團股份有限公司 含ｂｒａｆ抑制劑的藥物組合物及其在醫藥上的應用
WO2026037755A1 (fr) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag Nouveaux dérivés de méthylquinazolinone
WO2026046946A1 (fr) 2024-08-28 2026-03-05 F. Hoffmann-La Roche Ag Nouvelles formes solides de (3r)-n-[2-cyano-4-fluoro-3-(3-méthyl-4-oxo-quinazolin-6-yl)oxy-phényl]-3-fluoro-pyrrolidine-1-sulfonamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4429085B2 (ja) 2004-06-08 2010-03-10 有限会社コンペックス 茸栽培用殺菌菌床組成物の製造法及び茸栽培法
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2009012283A1 (fr) 2007-07-17 2009-01-22 Plexxikon Inc. Composés et procédés pour la modulation des kinases et leurs indications
EP3147281A1 (fr) 2008-03-17 2017-03-29 Ambit Biosciences Corporation Dérivés de quinazoline utilisés comme modulateurs de la kinase raf et leurs procédés d'utilisation
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2012118492A1 (fr) * 2011-03-01 2012-09-07 Array Biopharma Inc. Sulfonamides hétérocycliques en tant qu'inhibiteurs de raf
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
AU2013318283A1 (en) 2012-09-19 2015-03-05 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
CN105228983A (zh) 2013-05-30 2016-01-06 普莱希科公司 用于激酶调节的化合物及其适应症
US9814714B2 (en) 2015-05-22 2017-11-14 Plexxikon Inc. Kinase modulation, and indications therefor
RU2724345C2 (ru) 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
RU2687107C1 (ru) 2018-06-18 2019-05-07 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
WO2020142612A1 (fr) 2019-01-03 2020-07-09 Genentech, Inc. Composés de pyrido-pyrimidinone et de ptéridinone utilisés en tant qu'inhibiteurs de l'enzyme nécessitant l'inositol i (ire i alpha) à activité endoribonucléase pour le traitement de maladies cancéreuses
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
AU2020403082A1 (en) * 2019-12-10 2022-05-12 F. Hoffmann-La Roche Ag New BRAF inhibitors as paradox breakers
PH12022551119A1 (en) 2019-12-10 2023-08-23 Hoffmann La Roche New methylquinazolinone derivatives
TW202426436A (zh) 2020-06-09 2024-07-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和病症之化合物
WO2022129259A1 (fr) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag Nouveaux dérivés de quinazolinone
JP2023554062A (ja) 2020-12-18 2023-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規アリール－ピリド－ピリミジン－オン誘導体
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
US20250011304A1 (en) 2021-12-08 2025-01-09 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide

Also Published As

Publication number Publication date
UA128299C2 (uk) 2024-05-29
JP7108146B2 (ja) 2022-07-27
BR112022011123A2 (pt) 2022-08-23
EP4483882A2 (fr) 2025-01-01
FI4073065T3 (fi) 2025-04-16
KR102836833B1 (ko) 2025-07-22
SI4073065T1 (sl) 2025-06-30
PL4073065T3 (pl) 2025-05-19
PT4073065T (pt) 2025-04-15
JP2022531609A (ja) 2022-07-07
AR122351A1 (es) 2022-09-07
US20240174621A1 (en) 2024-05-30
DK4073065T3 (da) 2025-04-22
PH12022551119A1 (en) 2023-08-23
WO2021116055A1 (fr) 2021-06-17
JP2022124458A (ja) 2022-08-25
RS66721B1 (sr) 2025-05-30
TWI877268B (zh) 2025-03-21
US20220298119A1 (en) 2022-09-22
AU2020403443A1 (en) 2022-05-12
CA3162883A1 (fr) 2021-06-17
HRP20250418T1 (hr) 2025-06-06
CN118791472A (zh) 2024-10-18
PE20221778A1 (es) 2022-11-16
CL2022001529A1 (es) 2023-02-10
JP7802514B2 (ja) 2026-01-20
TWI908405B (zh) 2025-12-11
CN114787156A (zh) 2022-07-22
ZA202204675B (en) 2022-12-21
IL316473A (en) 2024-12-01
TW202504895A (zh) 2025-02-01
AU2020403443B2 (en) 2023-02-23
KR20220110554A (ko) 2022-08-08
CO2022008968A2 (es) 2022-07-19
US12116349B2 (en) 2024-10-15
EP4073065B1 (fr) 2025-02-19
LT4073065T (lt) 2025-04-25
MX2022006783A (es) 2022-07-11
EP4073065A1 (fr) 2022-10-19
TW202136245A (zh) 2021-10-01
CR20220251A (es) 2022-07-11
CN114787156B (zh) 2024-07-26
ZA202206923B (en) 2024-10-30
ES3023264T3 (en) 2025-05-30
IL292161B2 (en) 2025-04-01
NZ787393A (en) 2025-07-25
IL292161B1 (en) 2024-12-01
HUE071148T2 (hu) 2025-08-28
IL292161A (en) 2022-06-01
EP4483882A3 (fr) 2025-03-05

Similar Documents

Publication Publication Date Title
MA58087B1 (fr) Nouveaux dérivés de méthylquinazolinone
MA52948B1 (fr) Composés
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
CR20200588A (es) Compuestos novedosos
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
EA201892300A1 (ru) Макроциклические ингибиторы mcl1 для лечения рака
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA38472A1 (fr) Composé peptidique
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
MA42341B2 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MA38323A1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
MA39983A (fr) Dérivés de carboxamide
JOP20210039B1 (ar) مركبات بيريدين 6،2 - ديامينو
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MA40605B1 (fr) Composé pyrazolothiazole et médicament
EA202192760A1 (ru) Трициклические соединения